CASAMENTO CHARLES J — SEC Form 4 filings
SEC reporting owner CIK 1117167. 13 Form 4 filings on record with FilingPulse; latest filed 2026-08-04.
Transaction summary — filings shown
Covers all 13 filings on record, filed 2024-01-04 to 2026-08-04. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 13,000 shares, $33,280 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 14.
- Largest priced transaction: purchase of 13,000 shares @ $2.56 ($33,280) in RELMADA THERAPEUTICS, INC., filed 2024-09-11.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | Director | 5 | 1 leg · 13,000 sh · $33,280 | — | 5 |
| Eton Pharmaceuticals, Inc. (ETON) | Director | 4 | — | — | 5 |
| PaxMedica, Inc. (PXMD) | Director | 2 | — | — | 2 |
| First Wave BioPharma, Inc. (FWBI) | Director | 1 | — | — | 1 |
| GT Biopharma, Inc. (GTBP) | Director | 1 | — | — | 1 |
Form 4 filings — CASAMENTO CHARLES J
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-04 | 4 | Eton Pharmaceuticals, Inc. (ETON) | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2026-01-14 | 4 | Eton Pharmaceuticals, Inc. (ETON) | Grant/award (A): 12,196 (derivative) @ $0 · Grant/award (A): 7,757 (derivative) @ $0 | EDGAR |
| 2025-12-16 | 4 | RELMADA THERAPEUTICS, INC. (RLMD) | Grant/award (A): 164,000 (derivative) @ $0 | EDGAR |
| 2025-09-08 | 4 | GT Biopharma, Inc. (GTBP) | Grant/award (A): 62,500 (derivative) @ $0 | EDGAR |
| 2025-06-30 | 4 | RELMADA THERAPEUTICS, INC. (RLMD) | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2025-01-06 | 4 | Eton Pharmaceuticals, Inc. (ETON) | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-10-23 | 4 | RELMADA THERAPEUTICS, INC. (RLMD) | Gift (G): 13,000 @ $0 | EDGAR |
| 2024-09-11 | 4 | RELMADA THERAPEUTICS, INC. (RLMD) | Purchase (P): 13,000 @ $2.56 | EDGAR |
| 2024-05-29 | 4 | RELMADA THERAPEUTICS, INC. (RLMD) | Grant/award (A): 20,976 (derivative) @ $0 · Other (J): 20,976 (derivative) @ $0 | EDGAR |
| 2024-03-14 | 4 | PaxMedica, Inc. (PXMD) | Tax withholding (F): 992 @ $0.69 | EDGAR |
| 2024-02-15 | 4 | Eton Pharmaceuticals, Inc. (ETON) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-01-31 | 4 | PaxMedica, Inc. (PXMD) | Tax withholding (F): 97 @ $0.76 | EDGAR |
| 2024-01-04 | 4 | First Wave BioPharma, Inc. (FWBI) | Grant/award (A): 19,633 @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-04 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1117167 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →